Androxal: Phase I/II data

Updated data from a U.S. Phase I/II trial in 62 hypogonadal men showed that the low, mid and high doses of Adroxal caused mean serum testosterone increases of 169 ng/dl, 247 ng/dl and 294 ng/dl, respe...